MLN2201 is a humanized monoclonal antibody inhibitor that targets Integrinbeta2. It can inhibit reperfusion injury following a stroke and is applicable for researching inflammatory conditions such as ischemic stroke.
Target-Kategorie:
Integrin
* Mehrwertsteuer und Versandkosten nicht enthalten. Irrtümer und Preisänderungen vorbehalten
